(Q34987649)

5 August 2017

1 reference

title

The randomized world is not without its imperfections: reflections on the Women's Health Initiative Study (English)

1 reference

5 August 2017

Paul G McDonough

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

published in

Fertility and Sterility

1 reference

5 August 2017

volume

78

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

951-956

1 reference

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Approached to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Design of the Women’s Health Initiative Clinical Trial and Observational Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Methods of correcting for multiple testing: operating characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Controlling alpha in a clinical trial: the case for secondary endpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Multivariate survival analysis using Cox's regression model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

A Multiple Testing Procedure for Clinical Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Low P-values or narrow confidence intervals: which are more durable?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Regression models: calculating the confidence interval of effects in the presence of interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Agreement between breast cancer risk estimation methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Hierarchical proportional hazards regression models for highly stratified data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Converting relative risks to absolute risks: a graphical approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Correction of logistic regression relative risk estimates and confidence intervals for measurement error: the case of multiple covariates measured with error

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Hormone replacement therapy (oestradiol-only preparations): can the laboratory recommend a concentration of plasma oestradiol to protect against osteoporosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Monitoring of hormone replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Menopausal hormone replacement therapy and risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Forth nightly review: hereditary ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

The genetics of ovarian cancer: molecular biology and clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

Epidemiology. Despite safety concerns, U.K. hormone study to proceed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2802%2904403-5

10.1016/S0015-0282(02)04403-5

7 January 2021

Identifiers

DOI

1 reference

5 August 2017

1 reference